Background: The aim of this study was to validate the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based cohort and to study the relevance of revision and extension of the FLIPI. Results: The original FLIPI stratified our cohort into three different risk groups based on stage, Hb, lactate dehydrogenase, nodal involvement and age. The discrimination between risk groups was not as good as in the original cohort. A model including age in three categories (£60/61-70/>70 years) and presence of cardiovascular disease (CVD) (yes/no) resulted in a better prognostic index. The 5-year overall survival rates were 79%, 59% and 28% in the low-, intermediate-and high-risk groups for the extended FLIPI compared with 81%, 66% and 47% for the original FLIPI, respectively.
introduction Follicular lymphoma (FL) is an indolent lymphoma and accounts for one-third of non-Hodgkin lymphomas (NHLs) in adults. The prognosis for patients with FL is heterogeneous and treatment options vary from 'watchful waiting' to high-dose chemotherapy [1] . A validated prognostic index would help in evaluating and choosing between the different treatment options. Patients with a poor prognosis should be considered for more aggressive and experimental therapies while on the contrary, those with a good prognosis may benefit from watchful waiting or less toxic regimens.
Recently, a new clinical prognostic index has been proposed for FL: the Follicular Lymphoma International Prognostic Index (FLIPI) [1] . This index is based on large series of patients and proposes three risk groups according to the probability of survival. The score was defined on a training series of 1795 patients with complete values for age, Ann Arbor stage, marrow involvement, hemoglobin (Hb) level, number of nodal site areas, lymphocyte count and serum lactate dehydrogenase (LDH) level. The total cohort consisted of 4167 trial patients, but information from 2372 patients was discarded due to missing values. Excluding patients because of missing values can lead to bias and is statistically inefficient [2] . Nowadays, methods such as multiple imputation (MI) for handling of missing data have become more standard and software is more readily available [2, 3] .
In the original report, a five-variable model included the risk factors: age (>60), Ann Arbor stage (III-IV), Hb level (<12 g/dl), number of nodal site areas (>4) and serum LDH (elevated) [1] . The FLIPI has been validated in some subgroups [1, [4] [5] [6] [7] , but needs further validation in a population-based setting where we see a broader selection of patients, such as more elderly patients and more patients with comorbidity [8] . Comorbidity, if serious enough, is an independent prognostic factor [9] [10] [11] . For unselected Dutch patients with indolent NHL, the proportion of those with comorbid conditions was 39% for patients aged £60 and 69% for those >60 [12] . Therefore, it is important to consider extension of the FLIPI with comorbidity as a risk factor. The aim of this study was to validate the FLIPI in a population-based cohort and to study the relevance of revision and extension of the FLIPI.
patients and methods study population and data collection
The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in the southern part of the Netherlands, an area with 2.3 million inhabitants, 10 general hospitals and two large radiotherapy institutes [13] . Trained registration clerks actively collect data on diagnosis, topography, histology, stage and information about initial treatment (delivered within 6 months from diagnosis) from hospital medical records. The medical record is generally regarded as the most complete source of information on the patient's past and current health status [14] . Since 1993 the Eindhoven Cancer Registry also registers the presence of serious comorbidity with prognostic impact at the time of cancer diagnosis, using a slightly modified version of the widely used Charlson comorbidity index [9, 15] . Comorbidity was defined as any disease that was present at the time of cancer diagnosis. Comorbidities were registered as dichotomous variables (yes/no), according to the medical history of the patient, the use of relevant drugs and diagnostic work-up. Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) are diseases with significant influence on survival [12, 16] . These were analyzed separately for their impact on prognosis. CVD included myocardial infarction, cardiac insufficiency, angina pectoris, coronary artery bypass graft, peripheral arterial disease and cerebrovascular diseases.
All patients with FL newly diagnosed from 1993 to 2002 were included (n = 369). Patients with lymphoma diagnosed at autopsy were not selected. There were also some lymphomas, not otherwise specified and B-cell lymphoma, not otherwise specified patients recorded in our registry. Therefore, the represented series might reflect a slight under registration, but we are quite confident that nearly all FL patients were selected.
Additional data (Hb level, number of nodal areas and serum LDH level) were gathered from the medical records. The prognostic index was calculated according to the original FLIPI [1] , using the variables age >60 years, advanced stage (III-IV), increased serum LDH, Hb level <12 g/dl and nodal involvement (>4 sites). Three risk groups were considered: score 0-1, low risk; score 2, intermediate risk and score ‡3, high risk [1] .
Follow-up was completed up to 1 January 2006, with vital status obtained from the municipal personal records. Survival time was defined as the time from diagnosis till death or the end of the study.
statistical analysis
The influence of risk factors on overall survival (OS) was studied by Kaplan-Meier curves and log-rank tests in univariate analysis. For reasons of efficiency and to avoid potential bias, we imputed missing covariates using correlations between variables. We used a multiple imputation (MI) procedure where each missing value was imputed five times. Imputed values were drawn from the predictive distribution in an imputation model that included all risk factors and the survival outcome. The variation among the five imputations reflects the uncertainty with which the missing values can be predicted. MI resulted in five complete datasets, which were analyzed with standard complete data methods. The results were combined to produce overall estimates and standard errors that reflected missing data uncertainty [2] . All analyses were carried out for both complete cases as well as for single and MI. Results are reported with multiple imputated data, except for the Kaplan-Meier analyses, which were based on the first of the five imputated data sets.
MI was carried out with the aregImpute function in the R software package (v 2.5.1).
Validation of the FLIPI started with a comparison of the hazard ratios (HRs) of the risk factors. We checked whether the coefficients in the Cox regression equation needed to be updated, based on likelihood ratio (LR) statistics [17] . Next, we considered extension of the model with COPD (yes/ no), CVD (yes/no), B symptoms (yes/no), number of comorbidities (yes/no and no/one/more than one) and a combination of these variables.
We used the c-statistic to study discrimination, which reflected to the ability of the (extended) FLIPI to assign higher predicted risks to subjects who have died during the follow-up than to subjects who survived the whole follow-up period. We also calculated the explained variation by the covariates as R 2 = 1 2 exp (2LR/n). We used a bootstrap resampling procedure to correct for statistical optimism in the estimated c-statistic. Modeling was repeated in 200 bootstrap samples, with model testing in the original sample, for each of the five imputed data sets [18] . The SAS computer package (version 8.2, SAS Institute Inc., Cary, NC, 1999) and the R computer package (version 2.5.1) were used for statistical analyses.
results
From 1993 to 2002, 369 patients had been diagnosed with FL. Sixteen patients were excluded because information could not be gathered. The characteristics of the original FLIPI study population [1] and our 353 patients at diagnosis are compared in Table 1 . Median follow-up was 58 months, and 138 patients died. OS of the FL patients was similar in both studies (49% versus 51% 10-year survival rates). Age >60, advanced stage (III-IV), increased serum LDH, Hb level <12 g/dl, number of involved sites >4 and the presence of B symptoms, comorbidity and CVD were significantly associated with dismal OS in univariate analysis (Table 1) . For 77 patients, the FLIPI score could not be calculated due to missing values. The most frequent missing variable was a serum LDH level. The 276 FL patients with complete data were categorized as low (45%), intermediate (25%) and high risk (30%), according to the FLIPI score. With imputation, these proportions changed toward 47%, 26% and 27% for low-, intermediate-and high-risk groups, respectively. The low-risk group had a 5-and 10-year OS of 81% and 62%, respectively; the intermediate risk group had 5-and 10-year OS of 66% and 48%, respectively; those in the high risk group had the worst OS 47% and 34% ( Table 2) .
The FLIPI score discriminated less between the three risk groups in our population-based study as compared with the original cohort (c-statistic in our refitted model was 0.64). The c-statistic was somewhat higher for the refitted model with five risk factors (0.66, 95% confidence interval 0.62-0.71). The lower discrimination was in agreement with lower HRs than in the original study (Table 2) .
Age >60 years had a significantly stronger coefficient than originally estimated, while the other FLIPI covariates had similar or slightly smaller effects. To correct for the underestimation of age in the original FLIPI, we considered age in three categories (£60/61-70/>70 years, Table 3 ). Fifty-one percent of the patients were <60 (n = 181), 29% were between 60 and 70 years (n = 103) and 20% were >70 years (n = 69).
Next we investigated whether extending the model could improve the prognostic index. The This model can be used with scores between 0 and 7 ( Table  3) . If we categorized patients with a score <3 as low risk, the 5-and 10-year OS were 79% and 62%, respectively (Table 4 ). An intermediate-risk group contains patients with a score of 3 
The numbers with significant results are presented in bold. OS, overall survival; LDH, serum lactate dehydrogenase; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease. The extended model could better discriminate groups with different survival than the original FLIPI (Figure 1 ). discussion Prognostic models should be valid for daily clinical practice allowing for stratification of patients and comparison of prognosis and forming a basis for treatment decisions [19] . For our population-based setting, the FLIPI was reasonably valid, but the FLIPI could significantly be improved by a more refined coding of age (£60/61-70/>70 years) and by including the presence of CVD as a risk factor.
For the validation, we first examined the univariate relationship between possible prognostic factors and survival. A large tumor burden has long been recognized as an important adverse factor and can be estimated either directly considering by stage or tumor diameter or indirectly by means of surrogate laboratory markers [19] . Also other clinical parameters have been correlated with prognosis including the number of nodal or extranodal sites, bone marrow involvement and the involvement of certain specific locations [19] . Similar results were found in our study: Ann Arbor stage and number of involved sites are important univariate prognostic factors.
In different prognostic models, including this study, clinical and laboratory parameters, such as low Hb level, increased LDH level and B-symptoms, are known as indirect parameters associated with the extent of the disease and/or its biological behavior and have an independent poor prognostic value [1, [20] [21] [22] .
The most important patient-related prognostic factor in FL was age, both in the univariate analyses as well as in our validation study, as widely reported in several studies [20, 22] . With dichotomization, information of this continuous variable is lost [23] . Several age limits have been used to identify elderly patients with FL. Differently from aggressive lymphoma, an age limit of 70 years seems to better discriminate young versus elderly patients with FL [24] . In our study, we used three age groups which resulted in a more discriminating prognostic model than the original model. We note that the age distribution was different between the original cohort and our cohort. Our study included more elderly patients (44% versus 37% >60 years). The most likely reason for the higher proportion of patients with advanced age in our populationbased cohort is that the original report is based on data from clinical trials, with restrictive selection criteria. This may have led to a lower proportion of patients with advanced age and/or comorbidity. CVD was related with age in our study, but the prognostic value of age was independent from the presence of comorbidity and might reflect unknown comorbid or The original FLIPI is from [1] . The refitted and extended models are Cox regression models fitted to our population based data. The numbers with significant results are presented in bold. FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; CI, confidence interval; Hb, hemoglobin level; LDH, lactate dehydrogenase level; CVD, cardiovascular disease. In several studies, comorbidity was found to be an independent prognostic factor for survival of NHL [11, 12] . In our study, several indicators of comorbidity (number of comorbid conditions, presence of CVD and COPD) were investigated as possible extensions for the prognostic model. Although the presence of comorbidity was assessed from medical records, which is more clinically precise than selfreported or administrative databases, no information was available about the severity and duration of comorbidity. If we missed comorbidity in FL cases, they are likely to be less severe. In the univariate analyses, the independent influence of comorbidity on survival of FL was already visible. It remains to be debated whether the poor prognosis associated with advanced age and presence of comorbidity should be a reason for a different, more aggressive approach in elderly patients. This should preferably be investigated prospectively, studying which characteristics are important for treatment decisions. Studying cause-specific survival will also help to unravel this question.
Several studies have been carried out to design prognostic models for patients with FL based on clinical and laboratory parameters, to identify patients in whom more aggressive experimental therapies are warranted. The FLIPI has recently been compared with other prognostic indices such as the International Prognostic Index (IPI) and the Italian Lymphoma Intergroup Index (ILI) [25] . All three prognostic scores are easily applicable. In the comparison study, the FLIPI score was able to classify more patients in the high-risk group than IPI and ILI. However, the high-risk group according to the ILI system identified a group with a particular worse prognosis as compared with IPI or FLIPI, suggesting ILI may have a relevant role in selecting patients with a very poor prognosis. Likewise our extended FLIPI should also be validated in other populations and compared with other prognostic indices.
Overall, currently available prognostic indices for FL, even if based on large series of patients, suffer from their retrospective nature. Missing values can be a problem, but should be handled with modern statistical approaches such as MI, to make retrospective analyses more reliable [3] . Prospective, complete data collection naturally remains preferable to retrospective analysis. Furthermore, new predictors could not be included because these variables were unknown or not tested in the past. For an example b2-microglobuline, which was not investigated in our data and which has demonstrated to be a prognostic factor in FL patients [26] .
Another limitation is the fact that our study registered cases with FL before the advent of rituximab. In The Netherlands, rituximab was introduced in 2003. Therefore, the follow-up for these patients was too short for validation, and this should be done in the future.
In our study, no detailed information about the first-line treatment was available. Therefore, it could not be included in the validation of FLIPI. However, the influence of specific treatments on survival of FL was limited before the introduction of rituximab.
A feasible risk score ideally should have about the same proportion of patients in each risk group. This seems to be quite the case if the original FLIPI is used in the populationbased cohort. Using the extended FLIPI, very few patients are in the high-risk group, and the majority of patients are in the lowrisk group. However, we think that it is more important for a risk score that patients are discriminated clearly in prognosis than the fact that the proportion is almost equally distributed over the subgroups.
Despite these limitations, this extended FLIPI showed how important comorbidity and age are in unselected patients with FL and therefore should be considered as an important factor for treatment decisions in FL patients in the general health care environment.
In conclusion, the extended FLIPI better prognosticates unselected FL patients by using a more refined coding of age and by including CVD. Therefore, we propose that the extended FLIPI can be considered for decision making on treatment in patients with FL, although we recognize that preferably prospective validation and further extension is required to better classify patients according to their prognosis, especially in this new era of treatment with rituximab. 
